PMID- 35547000
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220716
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of 
      Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients 
      With Type 2 Diabetes.
PG  - 801271
LID - 10.3389/fendo.2022.801271 [doi]
LID - 801271
AB  - AIMS: We evaluated the efficacy and significant changes in the levels of 
      retinol-binding protein 4 (RBP-4) and insulin resistance in patients with type 2 
      diabetes mellitus (T2DM) treated with chiglitazar versus sitagliptin. METHODS: 
      Eighty-one T2DM patients with haemoglobin A1c (HbA1c) level of 7.5%-10.0% were 
      selected. Based on the study criteria, patients were randomly assigned to receive 
      chiglitazar (32 mg), chiglitazar (48 mg), or sitagliptin (100 mg) orally for 24 
      weeks. Sociodemographic and anthropometric characteristics, lipid profiles, 
      glucose profiles, and serum RBP-4 levels were determined at baseline and at the 
      end of the therapy. RESULTS: After treatment for 24 weeks, significant changes in 
      fasting blood glucose (FBG), fasting insulin (Fins), 2 h-blood glucose (2h-BG), 
      the score values of insulin resistance/insulin secretion/beta cell function 
      (HOMA-IR, HOMA-IS, and HOMA-beta), triglyceride (TG), free fatty acid (FFA), 
      high-density lipoprotein cholesterol (HDL-C), and RBP-4 levels were detected in 
      patients with chiglitazar administration and sitagliptin administration. Changes 
      in RBP-4 levels were positively correlated with changes in HOMA-IR and 2 h-BG in 
      linear regression. CONCLUSIONS: Chiglitazar showed a greater improvement in 
      parameters of diabetes than sitagliptin, and changes in serum RBP-4 levels were 
      associated with changes in insulin-sensitizing parameters. CLINICAL TRIAL 
      REGISTRATION: ClinicalTrials.gov, CT.gov identifier: NCT02173457.
CI  - Copyright (c) 2022 Zhou, Wang, Wang, Xu, Li, Zhou, Shan, Huang, Cai, Liu, Su, Li 
      and Ma.
FAU - Zhou, Yunting
AU  - Zhou Y
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Wang, Huiying
AU  - Wang H
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Wang, Yuming
AU  - Wang Y
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Xu, Xiaohua
AU  - Xu X
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Li, Fengfei
AU  - Li F
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Zhou, Junming
AU  - Zhou J
AD  - Department of Cadre Gastroenterology, Jinling Hospital, Medical School of Nanjing 
      University, Nanjing, China.
FAU - Shan, Ting
AU  - Shan T
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Huang, Rong
AU  - Huang R
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Cai, Tingting
AU  - Cai T
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Liu, Xiaomei
AU  - Liu X
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Su, Xiaofei
AU  - Su X
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Li, Huiqin
AU  - Li H
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Ma, Jianhua
AU  - Ma J
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT02173457
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220425
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Blood Glucose)
RN  - 0 (Carbazoles)
RN  - 0 (Insulin)
RN  - 0 (Propionates)
RN  - 0 (chiglitazar)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Carbazoles/chemistry
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Humans
MH  - Insulin/metabolism
MH  - *Insulin Resistance/physiology
MH  - Propionates/chemistry
MH  - Sitagliptin Phosphate/therapeutic use
PMC - PMC9081976
OTO - NOTNLM
OT  - RBP-4
OT  - chiglitazar
OT  - insulin sensitivity
OT  - sitagliptin
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/14 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/01/01
CRDT- 2022/05/13 11:08
PHST- 2021/10/25 00:00 [received]
PHST- 2022/03/17 00:00 [accepted]
PHST- 2022/05/13 11:08 [entrez]
PHST- 2022/05/14 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.801271 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Apr 25;13:801271. doi: 
      10.3389/fendo.2022.801271. eCollection 2022.